Brewing anti-toxin drugs using probiotic yeast
利用益生菌酵母酿造抗毒素药物
基本信息
- 批准号:10687670
- 负责人:
- 金额:$ 133.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:Animal ModelAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsAttenuatedBacteriaBacterial InfectionsBacterial ToxinsBiomanufacturingCell surfaceCellsClostridium difficileCoupledDiseaseDisease ProgressionDrug usageEngineered ProbioticsEngineeringEpithelial CellsFamilyGene DeletionGenomeGlucoseGrowthHealth PromotionHumanIndividualInfectionLeadLocationMass Spectrum AnalysisModelingPeptide LibraryPeptidesPharmaceutical PreparationsPlayPredispositionPrevalenceProbioticsProteinsRecurrenceRiboseSaccharomyces cerevisiaeSiteTherapeuticToxinVirulenceWorkYeastsantibiotic resistant infectionsantitoxincommensal bacteriacommensal microbesdelivery vehicleglycosyltransferasein vitro Assayinhibitornovel therapeuticspathogenpathogenic bacteriapreventsugarsynergismusability
项目摘要
Abstract
Bacterial infections of the gut afflict millions of individuals worldwide. While treatment with antibiotics is currently
highly effective, the increasing prevalence of antibiotic resistance is making these infections more difficult to
treat. Furthermore, antibiotics can damage an individual’s health-promoting commensal bacteria, making them
susceptible to C. difficile infections, which can be recurrent in 20% of cases. New drugs are therefore needed
which can synergize with or prolong the utility of antibiotics. Bacteria commonly express toxins during infection,
which play key roles in virulence by damaging host epithelial cells. In support of their importance, pathogen
virulence is attenuated or eliminated entirely when their toxin genes are deleted. These toxins act through a
variety of mechanisms, but one large and important family are the glycosyltransferase toxins, which cause
cytopathic effects by attaching sugars (commonly glucose or ribose) to key locations on host proteins. A
promising strategy, synergistic with antibiotics, is to neutralize the toxins, as this would halt the progression of
disease and avoid off-target effects on commensal microbes. Unfortunately, toxin-neutralizing drugs do not exist
for many bacterial pathogens. For the anti-toxin therapies that do exist, they can be prohibitively expensive, or
target mutable regions of the toxins. In this work, we propose to develop peptides that neutralize the highly
conserved enzymatic activity of bacterial toxins. To do so, we will exploit the observation that baker’s yeast (S.
cerevisiae) is susceptible to these toxins. Because S. cerevisiae is so easy to engineer, it is therefore possible
to screen massive peptide libraries and identify potent toxin inhibitors that rescue yeast growth. In fact, we have
performed a pilot screen and have already identified a lead peptide inhibitor of C. difficile TcdB. We will first
expand this screen to identify peptide inhibitors of 5 additional bacterial toxins. The potency of these inhibitors
will be investigated in cell-based models of toxin activity, and the inhibitory mechanism of promising leads will
be identified using in vitro assays, coupled with mass spectrometry. Finally, these leads will be encoded in the
genome of probiotic yeast, enabling continuous biomanufacturing of these drugs at the site of disease. Probiotic
yeast will also be engineered to display toxin binders on its cell surface, thereby sequestering additional toxin
and preventing toxin contact with human cells. The efficacy of the peptides and yeast delivery vectors will be
evaluated in animal models. Taken together, this work develops a generalizable platform for discovery,
characterization, and delivery of anti-toxin therapeutics that has the potential to prolong the usability of existing
antibacterial drugs.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nathan C. Crook其他文献
Programming Probiotics: Diet-Responsive Gene Expression and Colonization Control in Engineered emS. boulardii/em
编程益生菌:工程化的布拉氏酵母菌中饮食响应基因表达与定植控制
- DOI:
10.1021/acssynbio.4c00145 - 发表时间:
2024-06-21 - 期刊:
- 影响因子:3.900
- 作者:
Deniz Durmusoglu;Daniel J. Haller;Ibrahim S. Al’Abri;Katie Day;Carmen Sands;Andrew Clark;Adriana San-Miguel;Ruben Vazquez-Uribe;Morten O. A. Sommer;Nathan C. Crook - 通讯作者:
Nathan C. Crook
Nathan C. Crook的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
New technologies for targeted delivery of anti-bacterial agents
抗菌药物靶向递送新技术
- 批准号:
1654774 - 财政年份:2015
- 资助金额:
$ 133.37万 - 项目类别:
Studentship
Targeting bacterial phosphatases for novel anti-bacterial agents.
针对细菌磷酸酶的新型抗菌剂。
- 批准号:
8416313 - 财政年份:2012
- 资助金额:
$ 133.37万 - 项目类别:
Targeting bacterial phosphatases for novel anti-bacterial agents.
针对细菌磷酸酶的新型抗菌剂。
- 批准号:
8298885 - 财政年份:2012
- 资助金额:
$ 133.37万 - 项目类别:














{{item.name}}会员




